Precise quantification of copy number alterations (CNAs) in a tumor genome is difficult. We have applied a comprehensive copy number analysis method, digital multiplex ligation-dependent probe amplification (digitalMLPA), for targeted gene copy number analysis in clear cell renal cell carcinoma (ccRCC).
Following treatment with androgen receptor (AR) pathway inhibitors, ∼20% of prostate cancer patients progress by shedding their AR dependence. These tumors undergo epigenetic reprogramming turning castration-resistant prostate cancer adenocarcinoma (CRPC-Adeno) into neuroendocrine prostate cancer (CRPC-NEPC).
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer.
Prostate-specific antigen (PSA) bounce after definitive radiotherapy has been reported as a predictor of improved biochemical recurrence-free survival (BCRFS). We revisited this phenomenon to confirm its clinical impact on oncological outcomes in patients with long-term follow-up who were free of biochemical recurrence (BCR) at least 3 years after treatment.
The primary objective of this study is to detect biomarkers and develop models that enable the identification of clinically significant prostate cancer and to understand the biologic implications of the genes involved.
Patients with prostate cancer (PCa) receiving docetaxel chemotherapy invariably develop chemoresistance. The transcription co-activator lens epithelium-derived growth factor p75 (LEDGF/p75), also known as DFS70 and PSIP1, is upregulated in several human cancers, including PCa and promotes resistance to docetaxel and other drugs.
Real-world data on palliative systemic therapies (PST) in treating metastatic bladder cancer (mBC) is limited. This study investigates current trends in treating mBC with first- (1L) and second-line (2L) chemotherapy (CT) and immunotherapy (IT).
Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines.
No matter where you are in your prostate cancer journey, it’s always the right time to take an active interest in the latest research and treatment. The PCF Doctor-Patient Summit at the 28th Annual Scientific Retreat is VIRTUAL, FREE and open to ALL. Date: Thursday, October 28, 2021Time: 1:00-3:00pm Pacific Time Come meet PCF’s new CEO, […]
Despite treatment advances in prostate cancer, it is associated with approximately 79,000 deaths in Europe and 34,000 deaths in the USA each year, presenting a clear unmet need.1,2 Most patients with metastatic castration-resistant prostate cancer (mCRPC) are ≥ 70 years of age and the median age of those who die from the disease is 80 […]
